Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

PETTA, Salvatore
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.977
EU - Europa 12.834
AS - Asia 12.251
SA - Sud America 2.073
Continente sconosciuto - Info sul continente non disponibili 1.822
AF - Africa 344
OC - Oceania 46
Totale 57.347
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 27.316
SG - Singapore 4.550
RU - Federazione Russa 3.444
IT - Italia 2.984
CN - Cina 2.963
BR - Brasile 1.618
DE - Germania 1.544
HK - Hong Kong 1.214
FI - Finlandia 1.196
VN - Vietnam 1.062
PL - Polonia 782
BD - Bangladesh 664
FR - Francia 570
GB - Regno Unito 528
UA - Ucraina 430
IE - Irlanda 395
JP - Giappone 380
CA - Canada 343
IN - India 318
KR - Corea 255
SE - Svezia 194
AR - Argentina 166
NL - Olanda 158
TR - Turchia 137
RO - Romania 136
MX - Messico 117
AT - Austria 112
IQ - Iraq 108
BE - Belgio 81
ES - Italia 75
ZA - Sudafrica 75
ID - Indonesia 69
CI - Costa d'Avorio 65
EC - Ecuador 65
SA - Arabia Saudita 60
CO - Colombia 58
JM - Giamaica 54
PK - Pakistan 48
PH - Filippine 47
UZ - Uzbekistan 46
VE - Venezuela 45
IR - Iran 42
AU - Australia 40
MY - Malesia 39
EG - Egitto 38
MA - Marocco 38
KE - Kenya 35
PY - Paraguay 34
CL - Cile 33
CR - Costa Rica 30
GR - Grecia 30
DK - Danimarca 27
TH - Thailandia 27
AE - Emirati Arabi Uniti 25
CH - Svizzera 24
TN - Tunisia 23
NP - Nepal 22
AZ - Azerbaigian 21
HN - Honduras 21
JO - Giordania 20
BG - Bulgaria 19
CZ - Repubblica Ceca 19
PE - Perù 19
TT - Trinidad e Tobago 19
DZ - Algeria 18
NI - Nicaragua 18
LT - Lituania 17
AL - Albania 15
BO - Bolivia 15
KZ - Kazakistan 15
LB - Libano 15
UY - Uruguay 15
IL - Israele 14
KG - Kirghizistan 14
OM - Oman 11
EU - Europa 10
GE - Georgia 10
GT - Guatemala 10
SV - El Salvador 10
TW - Taiwan 10
BY - Bielorussia 9
NG - Nigeria 9
DO - Repubblica Dominicana 8
MD - Moldavia 7
MM - Myanmar 7
PA - Panama 7
QA - Qatar 7
SN - Senegal 7
XK - ???statistics.table.value.countryCode.XK??? 7
ET - Etiopia 6
NZ - Nuova Zelanda 6
PR - Porto Rico 6
A2 - ???statistics.table.value.countryCode.A2??? 5
BN - Brunei Darussalam 5
HU - Ungheria 5
MO - Macao, regione amministrativa speciale della Cina 5
PS - Palestinian Territory 5
RS - Serbia 5
SD - Sudan 5
TG - Togo 5
Totale 55.460
Salva come PNG Salva come JPEG
Città #
Singapore 3.280
Fairfield 3.120
Ashburn 3.109
San Jose 1.779
Woodbridge 1.499
Chandler 1.351
Seattle 1.249
Houston 1.241
Wilmington 1.167
Hong Kong 1.144
Cambridge 1.081
Ann Arbor 715
Zgierz 690
Palermo 648
Moscow 593
Council Bluffs 529
Beijing 459
Los Angeles 451
Medford 441
Helsinki 411
New York 398
Des Moines 393
Dublin 391
Ho Chi Minh City 370
Santa Clara 354
Secaucus 353
Tokyo 342
Altamura 340
Lauterbourg 329
Cologne 327
Dallas 291
Princeton 282
Boardman 271
Hanoi 262
Nanjing 258
Lawrence 256
Jacksonville 222
Frankfurt am Main 221
Hefei 189
Chicago 175
San Diego 168
Rome 161
Buffalo 155
Milan 140
São Paulo 135
The Dalles 135
Sunnyvale 110
Nuremberg 106
London 101
Jinan 100
Shenyang 94
Orem 92
Ludwigshafen am Rhein 91
Toronto 90
Dearborn 86
Phoenix 84
Changsha 81
Tulsa 76
Nanchang 75
Atlanta 74
Tianjin 72
Hebei 69
Lappeenranta 67
Warsaw 66
Abidjan 65
Zhengzhou 64
Chennai 63
Jiaxing 62
Brooklyn 61
Columbus 60
Denver 60
Brussels 58
Amsterdam 57
Shanghai 56
Montreal 52
Guangzhou 51
Izmir 51
Paris 48
Hangzhou 47
Haiphong 45
Johannesburg 45
Manchester 45
Munich 45
Saint Petersburg 44
San Paolo di Civitate 44
Seongnam 44
Mumbai 43
Baghdad 42
Da Nang 42
Redwood City 41
Rio de Janeiro 41
Kingston 40
Naples 40
Seoul 40
Vienna 40
Belo Horizonte 36
Central 36
Tashkent 36
Ningbo 35
Brasília 34
Totale 35.122
Salva come PNG Salva come JPEG
Nome #
"Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV" 1.276
Diet, Weight Loss, and Liver Health in NAFLD: Pathophysiology, Evidence and Practice 570
Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis 495
Liver stiffness quantification in patients with non-alcoholic steatohepatitis: comparison of shear wave elastography and transient elastography with liver biopsy correlation 388
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis 377
The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease 362
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030 349
Transmembrane 6 Superfamily Member 2 Gene Variant Disentangles Nonalcoholic Steatohepatitis From Cardiovascular Disease 337
Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease 335
HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals 335
Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C. 322
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial 322
Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. 313
The presence of white matter lesions is associated with the fibrosis severity of nonalcoholic fatty liver disease 309
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease 308
L’insulino-resistenza è il principale fattore indipendente correlato con l’aumentato rischio metabolico nelle donne affette da PCOS 305
A "systems medicine" approach to the study of non-alcoholic fatty liver disease 297
Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. 291
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation 290
Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients 284
Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis 281
Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 277
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 271
751 RETINOL-BINDING PROTEIN 4 (RBP4): A NEW MARKER OF G1 HCV-INDUCED STEATOSIS 268
Antidiabetic drugs in NAFLD: The accomplishment of two goals at once? 267
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis 265
Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women 264
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions 264
Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS 263
The cheating liver: imaging of focal steatosis and fatty sparing 262
PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 261
The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. 260
Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C 260
MAFLD: a multisystem disease 259
The Hepatic Expression of Vitamin D Receptor is Inversely Associated with the Severity of Liver Damage in Genotype 1 Chronic Hepatitis C Patients. 259
Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection 256
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 255
Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. 253
Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. 252
Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study 252
High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis 251
Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection 250
MERTK rs4374383 polymorphism affects the severity of fibrosis in nonalcoholic fatty liver disease 250
The course of oesophagogastric varices in patients with cirrhosis after DAA-induced HCV clearance 249
Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver 248
Cost-Effectiveness of Boceprevir or Telaprevir for Untreated Patients with Genotype 1 Chronic Hepatitis C 240
Metabolic Factors and Chronic Hepatitis C: A Complex Interplay 240
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 240
Retinol-binding protein 4 (RBP4) : a new marker of G1 HCV-induced steatosis 238
Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients 237
LIPIDOMICS OF FATTY LIVER IN NAFLD AND HCV INFECTION: LIVER SPHYNGOLIPIDS AND FATTY ACIDS 236
Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. 236
Association of vitamin D serum levels and its common genetic determinants with severity of liver fibrosis in genotype 1 chronic hepatitis C patients 235
Genetic background in nonalcoholic fatty liver disease: A comprehensive review 234
A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease 232
Fibrosis Evaluation by Transient Elastography in Patients With Long-Term Sustained HCV Clearance 230
Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease 230
qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis 228
High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C 227
Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1. 226
STORIA NATURALE DELLA CIRROSI EPATICA 225
Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C 223
Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort 221
Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis. 220
TM6SF2 rs58542926 is not associated with steatosis and fibrosis in largecohort of patients with genotype 1 chronic hepatitis C 219
Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. 217
Serum BLYS/BAFF levels in acute hepatitis C predict clinical outcome 215
The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. 214
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 211
Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values 206
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 206
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C 205
Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies 205
Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma 204
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents 203
Development and Validation of Hepamet Fibrosis Scoring System A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis 203
AISF position paper on HCV in immunocompromised patients 203
Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? the REAL Experience 202
Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients with Nonalcoholic Fatty Liver Disease 202
Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C 200
Serum γ-glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases. 200
Metformina e pioglitazone in soggetti affetti da diabete mellito tipo 2 con steatosi epatica 199
Methylenetetrahydrofolate reductase homozygosis and low-density lipoproteins in patients with genotype 1 chronic hepatitis C 199
Statin use and non-alcoholic steatohepatitis in at risk individuals 199
The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent 199
FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage 198
Hepatic expression of cyclooxygenase-2 in non alcoholic fatty liver disease 197
Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with Nonalcoholic fatty liver disease 196
Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population 196
Pharmacological therapy of non-alcoholic fatty liver disease: What drugs are available now and future perspectives 195
Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. 195
Cardiovascular diseases and HCV infection: a simple association or more? 193
Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis 193
Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FiS (HEpatitis C Virus Fingerstick Study) 192
Hyperuricemia in non-alcoholic fatty liver disease: authors' reply. 191
Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV-monoinfected patients 191
Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy 190
Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. 189
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 189
PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C 189
Totale 25.965
Salva come PNG Salva come JPEG
Categoria #
all - tutte 201.458
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 201.458
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.564 0 0 119 92 75 150 145 348 392 387 248 608
2022/20234.459 497 947 80 427 416 650 315 330 462 44 208 83
2023/20242.004 79 291 113 138 169 515 239 108 31 63 57 201
2024/20255.944 166 311 465 551 184 277 400 354 422 698 865 1.251
2025/202623.239 1.288 958 1.360 2.116 2.229 3.248 3.298 2.358 1.975 2.079 1.261 1.069
2026/20272.752 1.124 1.101 527 0 0 0 0 0 0 0 0 0
Totale 57.347